Consensus expectations point to Q3 2026 revenue of $722.40 million and EPS of $0.52, as the stock trades at $94.15 relative to a $118.50 analyst price target.
Investors are primarily tracking the commercial uptake of Voxzogo, which is undergoing a critical label expansion into broader orthopedic indications. The market is also evaluating BioMarin’s progress in its operational strategy aimed at maximizing profitability from its core enzyme replacement portfolio. Analysts expect commentary on the limited rollout of the gene therapy Roctavian following recent strategic shifts in the company's manufacturing and commercial focus.